Recruiting

Prenatal Cell Free DNA Screening

Sponsor:

Natera, Inc.

Code:

NCT06808880

Conditions

Single Gene NIPT

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Single-gene Noninvasive Prenatal Testing (sgNIPT)

Study Details

Brief summary:

The purpose of this research is to develop and validate a single gene Non-Invasive Prenatal Test. The development of this investigational single-gene noninvasive prenatal testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy (SMA), Sickle cell disease, alpha thalassemia (a-thalassemia) and beta thalassemia (b-thalassemia) could provide information about the possibility that a child will be born with a serious health condition, in some cases in the absence of reproductive partner screening.

In order to develop a test for this purpose, investigators will collect blood samples and medical information from pregnant women who have pregnancies at higher risk for single gene disorders, such as those who are carriers for these conditions or affected by these conditions themselves, medical data from their reproductive partners in some cases, and either genetic testing results or a cheek swab sample from the newborn(s).

Conditions

Single Gene NIPT

Study ID

NCT06808880

Start date

Jan 25, 2024

Status verified date

Apr, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Apr, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Age 18 or older at the time of informed consent
2. Maternal participant: Pregnant and blood draw at ≥ 9 weeks gestational age (GA)
3. Maternal participant is positive for a single-gene disorder and/or there are prenatal ultrasound findings suggestive for a fetal single-gene disorder, including but not limited to the genes listed in the primary and secondary objectives
4. Meet the criteria for one of the following:

  • Both maternal and reproductive partner (paternal) status are positive for the same single-gene disorder OR
  • A commercially available single-gene NIPT has been performed as part of clinical care and is reported as increased risk for an affected fetus/fetuses OR Maternal status is positive for one or more single-gene disorders and reproductive partner status is unknown OR
  • Prenatal ultrasound findings are suggestive of a fetal single-gene disorder (autosomal dominant, autosomal recessive, or X-linked condition) and enrollment is approved by the medical monitor.
5. Willing to permit release of neonatal health information and the performance of a newborn cheek swab within 6 months following delivery
6. Willing to sign informed consent and comply with study procedures

Exclusion Criteria:

1. Reproductive partner found to not be positive for the same autosomal recessive genetic disorder as the pregnant maternal carrier, or vice versa
2. Surrogate gestation or egg donor pregnancy
3. Negative preimplantation genetic testing for the single-gene disorder identified in one or both parents

Study Design

Enrollment

4000 participants

Anticipated

Interventions and Outcome Measures

Arms

Increased Risk for Single Gene Disorder

Interventions

Single-gene Noninvasive Prenatal Testing (sgNIPT)

Natera sgNIPT is intended for use in pregnant people whose 'fetus/ fetuses are identified as at increased risk for a single gene disorder when there is no reproductive partner (paternal) screening available or when there is positive reproductive partner screening, but prenatal diagnostic testing is not an option or when there is concern for a single-gene disorder in the fetus/ fetuses irrespective of carrier status (e.g., based on fetal ultrasound findings).

Primary outcome measure

  • Performance of sgNIPT assay in the detection of primary four autosomal recessive disorders [ Time Frame: Following the development of the sgNIPT assay, approximately 2 years after the launch of the study ]

Central Contacts and Locations

Central contacts

Locations

Valley Perinatal

Recruiting

Glendale, Arizona, United States, 85304

Contacts

Cedars Sinai Prenatal Diagnosis Center

Recruiting

Los Angeles, California, United States, 90048

Contacts

Center for Fetal Medicine and Womens Ultrasound

Recruiting

Los Angeles, California, United States, 90048

Contacts

Natera Inc

Recruiting

San Carlos, California, United States, 94070

Contacts

University of California San Francisco

Recruiting

San Francisco, California, United States, 94158

Contacts

Orlando Health Inc. (Winnie Palmer Hsopital)

Recruiting

Orlando, Florida, United States, 32806

Contacts

UMMC WH Univerity Center For Fetal Medicine

Recruiting

Jackson, Mississippi, United States, 39216

Contacts

Capital Health

Recruiting

Lawrenceville, New Jersey, United States, 08648

Contacts

Rutgers Robert Wood Johnson Medical School

Recruiting

New Brunswick, New Jersey, United States, 08901

Contacts

NYU Langone Hospital

Recruiting

Garden City, New York, United States, 11530

Contacts

Northwell (Northshore/LIJ)

Recruiting

New Hyde Park, New York, United States, 11040

Contacts

NYU Langone

Recruiting

New York, New York, United States, 10022

Contacts

Icahn School of Medicine at Mount Sinai

Recruiting

New York, New York, United States, 10029

Contacts

Weill Medical College of Cornell University

Recruiting

New York, New York, United States, 10065

Contacts

University of Rochester

Recruiting

Rochester, New York, United States, 14642

Contacts

Austin Maternal Fetal Medicine/St. Davids Healthcare

Recruiting

Austin, Texas, United States, 78758

Contacts

University of Texas Medical Branch (UTMB)

Recruiting

Galveston, Texas, United States, 77555

Contacts

PEDIATRIX Medical Services, Inc. Master + Houston

Recruiting

Stafford, Texas, United States, 77477

Contacts

More Information

Sponsor

Natera, Inc.

Last update posted

May 4, 2026

Last verified

Apr, 2026

Keywords

  • single gene NIPT

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Natera, Inc. on 2026-05-04.